Search for: "INDIANAPOLIS ENDOCRINOLOGY " Results 1 - 5 of 5
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Dec 2017, 9:20 am by Kevin S. Little
Doximity’s December 2017 study concluded that the following metropolitan areas had the job advertisement growth indicated below: Boston 72% San Francisco 42% Chicago 36% Washington, DC 23% New York 21% Denver 12% Seattle 4% Philadelphia 2% Miami 2% Los Angeles 1% The study indicated the following compensation growth by metropolitan areas: San Francisco 16% Indianapolis 14% Los Angeles 13% Philadelphia 11% Milwaukee 10% New York 8% Minneapolis 8% Seattle 7% Boston 7% The following… [read post]
29 Dec 2017, 9:20 am by Kevin S. Little
Doximity’s December 2017 study concluded that the following metropolitan areas had the job advertisement growth indicated below: Boston 72% San Francisco 42% Chicago 36% Washington, DC 23% New York 21% Denver 12% Seattle 4% Philadelphia 2% Miami 2% Los Angeles 1% The study indicated the following compensation growth by metropolitan areas: San Francisco 16% Indianapolis 14% Los Angeles 13% Philadelphia 11% Milwaukee 10% New York 8% Minneapolis 8% Seattle 7% Boston 7% The following… [read post]
4 May 2011, 10:00 am by Lucas A. Ferrara, Esq.
Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., and Indianapolis-based Eli Lilly Co. [read post]
6 Jan 2010, 2:05 pm by Tom Lamb
  From a December 23, 2009 Bloomberg article, "Amylin Falls as Analyst Says FDA Wants Byetta Study", by reporter Rob Waters: San Diego-based Amylin and Indianapolis-based Eli Lilly & Co., which co-market the drug, announced Oct. 30 that the Food and Drug Administration had cleared the drug for use as standalone therapy for Type 2 diabetics and that prescribing information would warn about the risk of pancreatitis, an inflamed pancreas, in patients with severe kidney… [read post]